Clinical Trials & the COVID-19 Vaccine

Findings Uncover More than 1 in 3 Americans Don’t Trust How Quickly COVID-19 Vaccine Clinical Trials Are Moving

LONDON, Oct. 01, 2020, the global business intelligence provider for the biopharma industry, today released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t trust how quickly the COVID-19 vaccine clinical trials are moving, and more than 1 in 5 (23%) don’t think pharmaceutical companies have consumers’ best interests at mind during COVID-19 vaccine clinical trials.

The study conducted with third-party research firm YouGov,found that while Americans are wary of the current vaccine development process, they are paying attention to it with 22% saying they regularly look for updates on COVID-19 vaccine clinical trials. As such, developers must prioritize further education and transparency around the process.

Read More

Informa Business Intelligence: Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

Findings Uncover More than 1 in 3 Americans Don’t Trust How Quickly COVID-19
Vaccine Clinical Trials Are Moving

LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the
global business intelligence provider for the biopharma industry, today
released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study
which uncovered American sentiment and confidence around COVID-19 vaccine
clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t
trust how quickly the COVID-19 vaccine clinical trials are moving, and more
than 1 in 5 (23%) don’t think pharmaceutical companies have consumers’ best
interests at mind during COVID-19 vaccine clinical trials.

The study conducted with third-party research firm YouGov, found that while
Americans are wary of the current vaccine development process, they are paying
attention to it with 22% saying they regularly look for updates on COVID-19
vaccine clinical trials. As such, developers must prioritize further education
Read More